Presentation is loading. Please wait.

Presentation is loading. Please wait.

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)  Dorothy A. White, MD, Lawrence.

Published byGabriella Corradini Modified over 6 years ago

Similar presentations

Presentation on theme: "Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)  Dorothy A. White, MD, Lawrence."— Presentation transcript:

1 Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)  Dorothy A. White, MD, Lawrence H. Schwartz, MD, Sasa Dimitrijevic, PhD, Lilla Di Scala, PhD, Wendy Hayes, Do, Stefan H. Gross, MSc  Journal of Thoracic Oncology  Volume 4, Issue 11, Pages (November 2009) DOI: /JTO.0b013e3181ba20b1 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Probable case. Left, New slight patchy focal infiltrate (Pattern B) on right side—12 weeks. Middle, Worsening focal infiltrate on right side and ground-glass opacities on left side—16 weeks. Right, Bilateral patchy infiltrates/ground-glass opacities—20 weeks (Supplement: case 1). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ba20b1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Probable case. Left top, Baseline—bibasilar interstitial infiltrates (interstitial lung disease). Middle, New ground-glass opacities (pattern A)—4 weeks. Right top, Bibasilar patchy infiltrates (pattern B)—12 weeks. Left bottom, Worsening infiltrates—16 weeks. Right bottom, After dose reduction of everolimus for fatigue improved infiltrates are noted (Supplement: case 3). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ba20b1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Possible case. Left top, Baseline—interstitial lung disease with focal changes right. Right top, New patchy focal unilateral abnormalities and small pleural effusion—4 weeks. Left bottom, Extensive infiltrates (pattern D)—8 weeks. Right bottom, Marked improvement with discontinuation of everolimus therapy drug held and antibiotic treatment—12 weeks (Supplement: case 5). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ba20b1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Possible case. Left, Baseline—interstitial lung disease (pattern E) possibly from prior radiation. Right, More extensive focal interstitial changes (pattern E) at 4 weeks (Supplement: case 9). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181ba20b1) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)  Dorothy A. White, MD, Lawrence."

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients  Benjamin T. Gielda, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
Joline S. W. Lind, MBBS, Egbert F

Joline S. W. Lind, MBBS, Egbert F
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Similar presentations

Ads by Google